Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Denecimig?
Denecimig is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Hemophilia A (Factor VIII Deficiency).
Denecimig is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Hemophilia A (Factor VIII Deficiency).
What's Your Reaction?
